Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.
Nov 2011 - :1791-2423 [PMID:22102168]
[Fournier P] [Arnold A] [Wilden H] [Schirrmacher V]

Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
Jul 2009 - J. Virol.; 83(16):1098-5514 [PMID:19515783]
[Jarahian M] [Watzl C] [Fournier P] [Arnold A] [Djandji D] [Zahedi S] [Cerwenka A] [Paschen A] [Schirrmacher V] [Momburg F]

Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
Sep 2008 - Int. J. Oncol.; 33(4):1019-6439 [PMID:18813797]
[Janke M] [Peeters B] [Zhao H] [de Leeuw O] [Moorman R] [Arnold A] [Ziouta Y] [Fournier P] [Schirrmacher V]

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
Nov 2007 - Gene Ther.; 14(23):0969-7128 [PMID:17914407]
[Janke M] [Peeters B] [de Leeuw O] [Moorman R] [Arnold A] [Fournier P] [Schirrmacher V]

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence.
Jun 2006 - Int. J. Cancer; 119(2):0020-7136 [PMID:16470838]
[Fiola C] [Peeters B] [Fournier P] [Arnold A] [Bucur M] [Schirrmacher V]

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
Dec 2005 - Int. J. Cancer; 118(3):0020-7136 [PMID:16108015]
[Haas C] [Lulei M] [Fournier P] [Arnold A] [Schirrmacher V]

T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Mar 2005 - Vaccine; 23(19):0264-410X [PMID:15752830]
[Haas C] [Lulei M] [Fournier P] [Arnold A] [Schirrmacher V]